Kabra Drugs share news and announcements
BSE: 524322Pharmaceuticals & BiotechnologySmall Cap
Last close ₹16.15down ₹0.49 (2.94%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹16.64.
52-week range of traded prices to 23 Oct 2026
₹15.50Low, 23 Oct 2026₹35.52High, 11 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹38 Cr3,225th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 5.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 1.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 28.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 28.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day.
- 58,004
Kabra Drugs routine notices
80 filed, newest first. Page 1 of 2.
Oct 2026
Sep 2026
28 Sep · Routine
Aug 2026
Jul 2026
Jun 2026
26 Jun · Routine
3 Jun · Routine
May 2026
Apr 2026
Mar 2026
25 Mar · Routine
Feb 2026
Jan 2026
Dec 2025
30 Dec · Routine
Nov 2025
17 Nov · Routine
Oct 2025
Sep 2025
26 Sep · Routine
Aug 2025
23 Aug · Routine
Jul 2025
Jun 2025
30 Jun · Routine
6 Jun · Routine
May 2025
Apr 2025
Mar 2025
31 Mar · Routine
Jan 2025
Dec 2024
31 Dec · Routine
Oct 2024
Sep 2024
30 Sep · Routine
Jul 2024
Jun 2024
29 Jun · Routine
May 2024
Apr 2024
Mar 2024
31 Mar · Routine
Jan 2024
Dec 2023
31 Dec · Routine
Oct 2023
3 Oct · Routine
Jul 2023
Jun 2023
May 2023
Apr 2023
Mar 2023
Jan 2023
Dec 2022
31 Dec · Routine
Oct 2022
Jul 2022
Jun 2022